Physician profile
Shannon M Riskey
NPI 1962819698
$1,123.97
in general payments reported to CMS, 2019-2025
16 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.27 · 2022: $362 · 2023: $218 · 2024: $187 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $404 · Education: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $404.34 |
| Education | $343.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $274.99 | 2025 | |
| Exelixis INC. | $151.48 | 2022-2023 | Cabometyx |
| Abbvie INC. | $125.62 | 2024 | |
| Merck Sharp & Dohme LLC | $114.62 | 2022 | |
| Amgen INC. | $90.22 | 2021-2023 | Lumakras, Kyprolis |
| Astrazeneca Pharmaceuticals Lp | $68.49 | 2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $54.61 | 2023 | |
| Eisai INC. | $46.39 | 2023-2024 | |
| Celgene Corporation | $42.02 | 2022-2024 | Opdivo |
| Incyte Corporation | $27.61 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $27.43 | 2022 | |
| Pfizer INC. | $27.00 | 2023 | |
| Genmab U.S., INC. | $23.11 | 2023 | Epkinly |
| Janssen Pharmaceuticals, INC | $21.62 | 2022 | |
| Daiichi Sankyo INC. | $14.55 | 2024 | Enhertu |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Riskey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.